QHSLab, Inc. reported a significant increase in revenue for the fiscal year ending December 31, 2024, generating $2.13 million, up from $1.41 million in 2023. This 51% growth was primarily driven by a 138% increase in Integrated Service Program (ISP) revenues, which reached $643,211, and a 25% rise in sales of Allergy Diagnostic Kits, totaling $832,987. Despite this revenue growth, the company continued to face challenges, posting a net loss of $259,239 for 2024, although this was an improvement compared to the $468,362 loss reported in the previous year.
The company has made strategic advancements, including the introduction of its QHSLab digital healthcare platform and the AllergiEnd® product line, which are designed to enhance the capabilities of primary care physicians (PCPs) in managing chronic diseases. QHSLab allows for remote patient monitoring and clinical decision support, which are increasingly recognized as essential in modern healthcare. The company aims to expand its user base by charging physicians subscription fees for the QHSLab platform and plans to introduce additional diagnostic tools and treatments.
Operationally, QHSLab reported a gross profit of $1.36 million in 2024, reflecting a gross margin increase from 56.3% in 2023 to 63.7% in 2024. The improvement in gross margin was attributed to a favorable product mix and enhanced cost structure following the acquisition of intangible assets from MedScience. The company also reported a notable increase in cash flow from operations, generating $142,437 in 2024 compared to a cash outflow of $159,627 in 2023, indicating a positive trend in operational efficiency.
As of December 31, 2024, QHSLab had total current assets of $420,827 and current liabilities of $2,407,308, resulting in a working capital deficit. The company is highly leveraged, with outstanding loans and convertible notes totaling $2.06 million. The financial statements raise substantial doubt about the company's ability to continue as a going concern, as it is currently in default on several loans. The management is actively seeking additional financing to support operations and is exploring options to restructure existing debt.
Looking ahead, QHSLab's management remains focused on increasing its revenue base through the expansion of its product offerings and customer acquisition strategies. The company acknowledges the competitive landscape in the healthcare technology sector and aims to leverage its unique value proposition to enhance its market position. However, the ongoing need for additional capital and the potential for further operational challenges remain critical factors that could impact the company's future performance.
About QHSLab, Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.